Back to Journals » OncoTargets and Therapy » Volume 12

A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer

Authors Fan Z, Liang Y, Yang X, Li B, Cui L, Luo L, Jia Y, Wang Y, Niu H

Received 3 September 2018

Accepted for publication 13 January 2019

Published 4 March 2019 Volume 2019:12 Pages 1791—1801

DOI https://doi.org/10.2147/OTT.S186271

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Geoffrey Pietersz


Zhongyuan Fan,1,* Ye Liang,1,* Xuecheng Yang,1 Bin Li,1 Lili Cui,2 Lei Luo,1 Yuefeng Jia,1 Yonghua Wang,1 Haitao Niu1

1Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China; 2Department of Urology, Dongying Vocational Institute, Dongying, China

*These authors contributed equally to this work

Background: This article is a meta-analysis aiming to systematically assess the efficacy and safety profiles of PD-1/PD-L1 inhibitors in patients with advanced or metastatic bladder cancer.
Methods: We extracted and examined data from phase I, II, and III clinical trials from the Medline, Embase, and the Cochrane Library, which included patients with metastatic bladder cancer who were treated with PD-1/PD-L1 inhibitors. We performed a meta-analysis to investigate several indexes of efficacy and safety, including the objective response rate (ORR), 1-year overall survival (OS) rate, 1-year progression-free survival (PFS) rate, and adverse event (AE) rate of immune checkpoint inhibitors. The material data were calculated and pooled using The R Project for Statistical Computing and Review Manager 5.3.
Results: After excluding ineligible records, 14 clinical trials were included in our analysis. The pooled frequencies of all-grade AEs and grade ≥3 AEs were 0.63 (95% CI 0.61–0.65, P=0.34) and 0.14 (95% CI 0.11–0.17, P=0.0072), respectively. The summary ORR was 0.21 (95% CI 0.18–0.24 P=0.07), and the 1-year OS and 1-year PFS rates were 0.48 (95% CI 0.42–0.54 P=0.0013) and 0.21 (95% CI 0.16–0.26 P=0.04), respectively. The OR of ORR between the PD-L1-positive and -negative groups was 3.09 (95% CI 2.01–4.75, P=0.08).
Conclusion: The PD-1/PD-L1 therapy showed appropriate efficacy and acceptable incidence of treatment-related AEs. In addition, the level of discrimination of PD-L1 expression might be related to the effect of the PD-1/PD-L1 inhibitors, and patients displaying positive expression might experience a better curative effect than patients displaying negative expression.

Keywords: PD-1 inhibitor, PD-L1 inhibitor, immunotherapy, metastatic bladder cancer, meta-analysis, bladder cancer, oncology

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]